RecruitingNot applicableEN originalLeukemia

MRD-positive AML Clinical Study

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the following drugs and protocols: Chemotherapy, small molecule targeted drugs, demethylation drugs, liposome drugs and the combination of these drugs to form a combination of treatment regimen, the specific treatment regimen will be updated according to the results of this trial and the latest research progress at home and abroad.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Zdiagnozowana białaczka ostra mieloidalna (AML) niebędąca typem M3, zgodnie ze standardami WHO 2016
  • Choroba w całkowitej remisji morfologicznej (brak widocznych komórek nowotworu w badaniu mikroskopowym)
  • Pozytywne wyniki testów na pozostałą chorobę minimalną (badania szpiku kostnego, geny fuzji lub mutacje FLT3)
  • Wiek ponad 14 lat, płeć obojętna
  • Podpisana świadoma zgoda pacjenta lub opiekuna prawnego

✗ Disqualifies

  • Planowany przeszczep szpiku kostnego w ciągu 4 tygodni
  • Rozpoznanie białaczki promielocytowej (APL)
  • Pacjenci ocenieni przez badaczy jako niestosowni do udziału w badaniu

Simplified criteria — AI translation

Trial details

Minimum age
14 Years
Last updated (source)
August 10, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (1)

Blood Diseases Hospital

Tianjin, China

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/11/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.